• TREATMENT

    FDA grants fast track designation to onvansertib plus FOLFIRI/bevacizumab for first-line RAS-mutated metastatic colorectal cancer

    The oral PLK1 inhibitor combined with standard chemotherapy showed a confirmed response rate of 72.2% versus 42.1% with chemotherapy alone in the phase 2 CRDF-004 trial, representing a 30.1-percentage-point improvement in patients with KRAS- or NRAS-mutated disease. (Targeted Oncology)